AF
ITCI

Avanza Fonder’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Avanza Fonder’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,043
Closed -$254K – 467
2024
Q4 		$254K Buy
+3,043
New +$250K 0.01% 387

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Avanza Fonder's ITCI Position: Q1 2025 in Review

Avanza Fonder sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 3,043 shares — an estimated $254K sold.

Avanza Fonder first reported a position in ITCI in Q4 2024 and held it in 1 quarter. The position peaked at $254K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Avanza Fonder reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Avanza Fonder sold 3,043 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $254K.
  • Avanza Fonder first reported a position in Intra-Cellular Therapies Inc. in Q4 2024 and held it in 1 quarter.
  • Avanza Fonder's Intra-Cellular Therapies Inc. position peaked at $254K in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Avanza Fonder's 13F filing for Q1 2025, filed 15 Apr 2025.